Evox Therapeutics Ltd, an Oxford, UK-based exosome therapeutics company, raised £69.2m ($95.4m) in Series C financing round.
The round was led by Redmile Group with participatiom from new investors OrbiMed and Invus and existing investors Oxford Sciences Innovation (OSI), GV (formerly Google Ventures) and Cowen Healthcare Investments. Eli Lilly, also converted a $10m convertible note into equity as part of the round. In connection with the financing, Evox will appoint Chau Khuong, partner at OrbiMed, to its Board of Directors.
The company intends to use the funds to advance its exosome-based therapeutics pipeline, including progression of several rare disease assets into the clinic, and continued development of its DeliverEXTM exosome drug platform.
Led by Dr Antonin de Fougerolles, Chief Executive Officer, Evox biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. The company uses its proprietary DeliverEXTMtechnology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies.